Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas

BACKGROUND. Mucins are considered important markers for early diagnosis and targeted therapy due to their aberrant and unique expression pattern during malignant progression of carcinomas. Recent findings have provided substantial evidence for the involvement of transmembrane mucins, MUC1 and MUC4, in altered cell signaling, tumor growth, and metastasis. METHODS. Immunohistochemical analyses were performed on prostate tumor tissues for expression profiling of the two transmembrane mucins, MUCI and MUC4. In cancer cell lilies, the expression was studied by RT-PCR and immunoblot analyses. Cells were treated with DNA-methylase and histone-deacetylase inhibitors to examine the implication of epigenetic mechanism(s) in MUC4 regulation. RESULTS. The expression of MUC4 was significantly downregulated in prostate cancer tissues (n = 38, P = 0.0026) compared to normal/benign prostatic hyperplastic regions. A faint to moderate staining was observed in 26.3% cases of cancer, while 84.2% cases of adjacent normal were positive for MUC4 with moderate to strong staining in most cases. Similar observations were made in immortalized normal prostate epithelial and cancer cell lilies. MUC1 also showed a reduced expression in prostate tumor tissues; however, its expression Was comparable in all normal prostate epithelial and cancer cell lilies. Interestingly, We also found that epigenetic mechanism(s) might be implicated in MUC4 gene silencing CONCLUSIONS. Our data suggest that MUC4 downregulation may be of significance for diagnostic applications in prostate cancer.